US 11,666,567 B2
Bromocriptine formulations
Anthony H. Cincotta, Tiverton, RI (US); Craig Michael Bowe, Encinitas, CA (US); Paul Clark Stearns, San Diego, CA (US); and Laura Jean Weston, Escondido, CA (US)
Assigned to VeroScience LLC, Tiverton, RI (US)
Filed by VeroScience LLC, Tiverton, RI (US)
Filed on Apr. 9, 2021, as Appl. No. 17/227,089.
Application 17/227,089 is a continuation of application No. 16/878,451, filed on May 19, 2020, granted, now 11,000,522.
Application 16/878,451 is a continuation of application No. 16/393,463, filed on Apr. 24, 2019, granted, now 10,688,094, issued on Jun. 23, 2020.
Application 16/393,463 is a continuation of application No. 15/981,752, filed on May 16, 2018, granted, now 10,307,421, issued on Jun. 4, 2019.
Application 15/981,752 is a continuation of application No. 15/618,055, filed on Jun. 8, 2017, granted, now 9,993,474, issued on Jun. 12, 2018.
Application 15/618,055 is a continuation of application No. 15/286,826, filed on Oct. 6, 2016, granted, now 9,700,555, issued on Jul. 11, 2017.
Application 15/286,826 is a continuation of application No. 14/920,123, filed on Oct. 22, 2015, granted, now 9,522,117, issued on Dec. 20, 2016.
Application 14/920,123 is a continuation of application No. 14/088,269, filed on Nov. 22, 2013, granted, now 9,192,576, issued on Nov. 24, 2015.
Application 14/088,269 is a continuation of application No. 13/773,500, filed on Feb. 21, 2013, granted, now 8,613,947, issued on Dec. 24, 2013.
Application 13/773,500 is a continuation of application No. 13/460,452, filed on Apr. 30, 2012, granted, now 8,431,155, issued on Apr. 30, 2013.
Prior Publication US 2021/0228576 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/48 (2006.01); A61K 31/4985 (2006.01); A61K 9/20 (2006.01); A61K 9/14 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 9/14 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2059 (2013.01); A61K 9/2072 (2013.01); A61K 9/2077 (2013.01); A61K 9/2095 (2013.01); A61K 31/48 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A dosage form comprising:
bromocriptine and one or more excipients;
wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject;
wherein the bromocriptine has a DV90 less than 15 μm and Dv10 of less than 2 μm; and
wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (Tmax) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the Tmax of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.